The synthesis of a novel class of piperazine benzamide (reverse amides) targeting the human β3-adrenergic receptor for the treatment of overactive bladder (OAB) is described. The SAR studies directed towards maintaining well established β3 potency and selectivities while improving the overall pharmacokinetic profile in the reverse amide class will be evaluated. The results and consequences associated with functional activity at the norepinephrine transporter (NET) will also be discussed.
Bioorganic & medicinal chemistry letters. 2016 Dec 11 [Epub ahead of print]
Bart H Harper, Liping Wang, Cheng Zhu, Nam F Kar, Bing Li, Christopher R Moyes, Stephen D Goble, Melissa Costa, Karen Dingley, Jerry Di Salvo, Sookhee N Ha, Amanda Hurley, Xiaofang Li, Randy R Miller, Hiroshi Nagabukuro, Gino M Salituro, Sean Smith, Mary Struthers, Jeffrey J Hale, Scott D Edmondson, Richard Berger
Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States. Electronic address: ., Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States.